JPWO2020208088A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020208088A5 JPWO2020208088A5 JP2021560513A JP2021560513A JPWO2020208088A5 JP WO2020208088 A5 JPWO2020208088 A5 JP WO2020208088A5 JP 2021560513 A JP2021560513 A JP 2021560513A JP 2021560513 A JP2021560513 A JP 2021560513A JP WO2020208088 A5 JPWO2020208088 A5 JP WO2020208088A5
- Authority
- JP
- Japan
- Prior art keywords
- benzyl
- trifluoromethyl
- carboxamido
- cyclopropyl
- azaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024129174A JP7750570B2 (ja) | 2019-04-09 | 2024-08-05 | 腫瘍を処置するためのｅｐ４アンタゴニストと免疫チェックポイント阻害剤の配合医薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19168253.3 | 2019-04-09 | ||
| EP19168253.3A EP3722319A1 (en) | 2019-04-09 | 2019-04-09 | Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours |
| PCT/EP2020/060054 WO2020208088A1 (en) | 2019-04-09 | 2020-04-08 | Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024129174A Division JP7750570B2 (ja) | 2019-04-09 | 2024-08-05 | 腫瘍を処置するためのｅｐ４アンタゴニストと免疫チェックポイント阻害剤の配合医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527716A JP2022527716A (ja) | 2022-06-03 |
| JPWO2020208088A5 true JPWO2020208088A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2023-03-30 |
| JP7671068B2 JP7671068B2 (ja) | 2025-05-01 |
Family
ID=66286074
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560513A Active JP7671068B2 (ja) | 2019-04-09 | 2020-04-08 | 腫瘍を処置するためのｅｐ４アンタゴニストと免疫チェックポイント阻害剤の配合医薬 |
| JP2024129174A Active JP7750570B2 (ja) | 2019-04-09 | 2024-08-05 | 腫瘍を処置するためのｅｐ４アンタゴニストと免疫チェックポイント阻害剤の配合医薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024129174A Active JP7750570B2 (ja) | 2019-04-09 | 2024-08-05 | 腫瘍を処置するためのｅｐ４アンタゴニストと免疫チェックポイント阻害剤の配合医薬 |
Country Status (12)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022257961A1 (zh) * | 2021-06-08 | 2022-12-15 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的苯并杂环化合物 |
| CN116251120A (zh) * | 2023-01-30 | 2023-06-13 | 中国医学科学院基础医学研究所 | 含锂化合物在肿瘤治疗中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008104055A1 (en) | 2007-02-26 | 2008-09-04 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| WO2011115069A1 (ja) * | 2010-03-19 | 2011-09-22 | 第一三共株式会社 | 結晶の網羅的探索 |
| BR112014000087B1 (pt) | 2011-07-04 | 2021-08-17 | Rottapharm Biotech S.R.L. | Derivados de amina cíclica como antagonistas do receptor ep4 |
| JP2014189462A (ja) * | 2013-03-27 | 2014-10-06 | Osaka Univ | 結晶製造方法、準安定形結晶、医薬の製造方法および医薬 |
| RU2748731C2 (ru) * | 2016-07-07 | 2021-05-31 | Оно Фармасьютикал Ко., Лтд. | Комбинация, содержащая антагонист ep4 и ингибитор иммунных контрольных точек |
| US10342785B2 (en) * | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| US11479550B2 (en) | 2017-05-22 | 2022-10-25 | Ono Pharmaceutical Co., Ltd. | EP4 antagonist |
| AU2019255196A1 (en) | 2018-04-16 | 2020-11-12 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
-
2019
- 2019-04-09 EP EP19168253.3A patent/EP3722319A1/en not_active Withdrawn
-
2020
- 2020-04-08 CA CA3136164A patent/CA3136164A1/en active Pending
- 2020-04-08 EP EP20730185.4A patent/EP3953393B1/en active Active
- 2020-04-08 AU AU2020273246A patent/AU2020273246B2/en active Active
- 2020-04-08 CN CN202080036803.6A patent/CN113874043A/zh active Pending
- 2020-04-08 DK DK20730185.4T patent/DK3953393T3/da active
- 2020-04-08 PL PL20730185.4T patent/PL3953393T3/pl unknown
- 2020-04-08 CN CN202510268959.1A patent/CN120093746A/zh active Pending
- 2020-04-08 JP JP2021560513A patent/JP7671068B2/ja active Active
- 2020-04-08 US US17/601,487 patent/US11590114B2/en active Active
- 2020-04-08 KR KR1020217036184A patent/KR20210151137A/ko active Pending
- 2020-04-08 WO PCT/EP2020/060054 patent/WO2020208088A1/en not_active Ceased
- 2020-04-08 BR BR112021020107A patent/BR112021020107A2/pt unknown
- 2020-04-08 ES ES20730185T patent/ES2939490T3/es active Active
-
2022
- 2022-10-26 US US17/973,714 patent/US20230122048A1/en active Pending
-
2024
- 2024-08-05 JP JP2024129174A patent/JP7750570B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102241258B1 (ko) | 암을 치료하기 위한 1-테트라히드로피라닐카르보닐-2,3-디히드로-1h-인돌 화합물 | |
| TWI829655B (zh) | 用於選擇性蛋白質降解的組合物及方法 | |
| AU2004201789B2 (en) | Fc receptor modulators and uses thereof | |
| CA3103674A1 (en) | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| TW202043280A (zh) | 對受體酪胺酸激酶樣孤兒受體１（ｒｏｒ１）具專一性之抗體及嵌合抗原受體 | |
| JP2022532247A (ja) | Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用 | |
| JP2019528301A (ja) | インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法 | |
| AU2015342944A1 (en) | Immunoregulatory agents | |
| CA3096546A1 (en) | Ep4 inhibitors and use thereof | |
| JP7750570B2 (ja) | 腫瘍を処置するためのｅｐ４アンタゴニストと免疫チェックポイント阻害剤の配合医薬 | |
| CA3177442A1 (en) | Il4i1 inhibitors and methods of use | |
| EP0560929A1 (en) | Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity | |
| TWI888358B (zh) | 使用c-c趨化激素受體4(ccr4)拮抗劑及一或多個檢查點抑制劑之組合療法 | |
| JPWO2020208088A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| US20240269099A1 (en) | Methods and compositions for treating cancer | |
| RU2021132187A (ru) | Фармацевтическая комбинация антагониста ер4 и ингибиторов иммунных контрольных точек для лечения опухолей | |
| EA044284B1 (ru) | Твердые формы, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и его соли, и содержащие их композиции и способы их применения |